Monoclonal anti-TNFα antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy

Klinika Oczna

Volumn 109, Issue 10-12, 2007, Pages 457-460

  Komorowski, Jan ^a   Jankiewicz Wika, Joanna ^a   Siejka, Agnieszka ^a   ŁAwnicka, Hanna ^a   Kłysik, Anna ^a   Goś, Roman ^a   Majos, Agata ^a   Stefańczyk, Ludomir ^a   Stȩpień, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Anty TNF ; Oftalmopatia Graves'a; TNF

Indexed keywords

ANTIINFLAMMATORY AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; CASE REPORT; ENDOCRINE OPHTHALMOPATHY; FEMALE; HUMAN; MIDDLE AGED; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34547347302     PISSN: 00232157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Komorowski J, Jankiewicz-Wika J, Suprunowicz I., Góraj B, Ścibor J & Stȩpień H: Effects of methylprednisolone treatment on peripheral blood levels of matrix metalloproteinases (MMP-1,-2,-3,-8,-9) tissue inhibitors of MMPs (TIMP-1, TIMP-2), angiogenic cytokines (VEGF, bFGF) and adhesion molecules (sICAM-1, sVCAM-1) in patients with thyroid-associated ophthalmopathy (TAO). Pol J Endocrinol 2003, 54, 13-21.
2. Durrani OM., Reuser TQ & Murray PI: Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 2005, 24, 117-119.
3. Komorowski J, Jankiewicz J, Robak T, Błasińska-Morawiec M, Stȩpień H: Cytokines serum levels as the markers of thyroid activation in Graves' disease. Immunol Lett 1998, 60, 143-148.
4. Komorowski J: Interleukins in Graves' disease. In Methods in molecular medicine. Interleukin protocols. vol. 60, pp. 251-261. Eds LAJ O'Neill & A. Bowie. Totova. New Jersey. Humana Press: 2001.
5. Mounts MR, Prummel MF, Wiersinga MW & Koomneef L: Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol 1997, 47, 9-14.
6. Krassas GE & Heufelder AE: Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 2001, 144, 311-318.
7. El Fassi D, Nielsen CH, Hasselbalch HC & HegedUs L: The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody as a novel treatment option. Eur J Endocrinol 2006, 154, 623-632.
8. Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, Sbrozzi F, Guastella C, Avignone S, Pirola G, Ratiglia R & Beck-Peccoz P: Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006, 154, 511-517.
9. Paridaenes D, Van den Bosch WA, Van der Loos TL Krenning ER Van Hagen PM: The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 2004; 1-4.
10. Laitt RD, Hoh B, Wakeley C, Kabala J Harrad R, Potts M Et Goddard P: The value of the short tau inversion recovery sequence in magnetic resonance imaging of thyroid eye disease. Brit J Radiol 1994, 67, 244-247.
11. Yokohama N, Nagataki S, Ashizawa K & Eguch K: Role of magnetic resonance imaging in the assessment of disease activity in thyroid-associated ophtalmopathy. Thyroid 2002, 12, 223-227.
12. Hosten N, Sander B, Cordes M, Schubert CJ, Schorner W & Felix R: Graves' ophtalmopathy. MR imaging of the orbits. Radiology 1989, 172, 759-762.
13. Prummel M, Gerding MN, Zonneveld FW & Wiersinga WM: The usefulness of quantitative orbital magnetic resonance imaging in Graves' ophtalmopathy. Clin Endocrinol 2001, 54, 205-209.
14. Utech Cl, Khatibnia U, Winter PF & Wulle KG: MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves' ophtalmopathy. Thyroid 1995, 5, 185-193.
15. Rutgeerts R Sandborn WJ, Feagan BG Reinisch W, Olson A, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Viliers WJ, Present D, Sands BE & Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353, 2462-24676.